- Email: [email protected]
Curcumin for Inflammatory Bowel Disease: A Caution
Accepted Manuscript Curcumin for inflammatory bowel disease-a caution Peter R. Holt
PII: DOI: Reference:
S1542-3565(15)01195-7 10.1016/j.cgh.2015.08.036 YJCGH 54454
To appear in: Clinical Gastroenterology and Hepatology Accepted Date: 27 August 2015 Please cite this article as: Holt PR, Curcumin for inflammatory bowel disease-a caution, Clinical Gastroenterology and Hepatology (2015), doi: 10.1016/j.cgh.2015.08.036. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
Curcumin for inflammatory bowel disease-a caution
Peter R Holt
Peter R Holt MD The Rockefeller University Box 179
New York, NY 10065 Tel. No. 6464384653
M AN U
Fax no. 2123277165
SC
1230 York Avenue
RI PT
The Rockefeller University
[email protected]
I have no conflict of interest to declare
EP
TE D
The paper by Lang et. al. (1) reports on the success of an international multicenter prospective double blind study of 3 g. per day of a 95% pure curcumin compound added to 4 g. of maintenance mesalamine to treat patients with mild to moderate ulcerative colitis. At the end of a one month study, a remarkable 53.8% of patients receiving curcumin achieved a clinical remission compared to none in the control group with parallel endoscopic improvement. This study, highlighted with an editorial (2) and frontispiece in CGH and in the August issue of GI and Hepatology News confirms the potential of curcumin as a therapeutic modality in IBD shown in previous studies (3) (4) and larger therapeutic trials are urgently needed.
AC C
One important caveat is that very pure curcumin compounds were used in these reported studies. Pharmacy and nutritional food store shelves are filled with a large number of products containing curcumin but also numerous additives. This is the time to caution our IBD patients that many curcumin containing compounds commercially available are very impure. Hype may cause harm.
References
1). Lang A et al. CGH 2015: 13, 1444-1449 2). Bernstein CN CGH 2015:13, 1450-1452 3). Holt PR et al. Dig.Dis. Sciences 2005:50, 2191-2193
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
4). Hanoi H et al CGH 2006: 4,1502-1506
PII: DOI: Reference:
S1542-3565(15)01195-7 10.1016/j.cgh.2015.08.036 YJCGH 54454
To appear in: Clinical Gastroenterology and Hepatology Accepted Date: 27 August 2015 Please cite this article as: Holt PR, Curcumin for inflammatory bowel disease-a caution, Clinical Gastroenterology and Hepatology (2015), doi: 10.1016/j.cgh.2015.08.036. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
Curcumin for inflammatory bowel disease-a caution
Peter R Holt
Peter R Holt MD The Rockefeller University Box 179
New York, NY 10065 Tel. No. 6464384653
M AN U
Fax no. 2123277165
SC
1230 York Avenue
RI PT
The Rockefeller University
[email protected]
I have no conflict of interest to declare
EP
TE D
The paper by Lang et. al. (1) reports on the success of an international multicenter prospective double blind study of 3 g. per day of a 95% pure curcumin compound added to 4 g. of maintenance mesalamine to treat patients with mild to moderate ulcerative colitis. At the end of a one month study, a remarkable 53.8% of patients receiving curcumin achieved a clinical remission compared to none in the control group with parallel endoscopic improvement. This study, highlighted with an editorial (2) and frontispiece in CGH and in the August issue of GI and Hepatology News confirms the potential of curcumin as a therapeutic modality in IBD shown in previous studies (3) (4) and larger therapeutic trials are urgently needed.
AC C
One important caveat is that very pure curcumin compounds were used in these reported studies. Pharmacy and nutritional food store shelves are filled with a large number of products containing curcumin but also numerous additives. This is the time to caution our IBD patients that many curcumin containing compounds commercially available are very impure. Hype may cause harm.
References
1). Lang A et al. CGH 2015: 13, 1444-1449 2). Bernstein CN CGH 2015:13, 1450-1452 3). Holt PR et al. Dig.Dis. Sciences 2005:50, 2191-2193
ACCEPTED MANUSCRIPT
AC C
EP
TE D
M AN U
SC
RI PT
4). Hanoi H et al CGH 2006: 4,1502-1506